Cargando…

Impact of Intravenous Trehalose Administration in Patients with Niemann–Pick Disease Types A and B

Background and Aims: Niemann–Pick disease (NPD) types A (NPA) and B (NPB) are caused by deficiency of the acid sphingomyelinase enzyme, which is encoded by the SMPD1 gene, resulting in progressive pathogenic accumulation of lipids in tissues. Trehalose has been suggested as an autophagy inducer with...

Descripción completa

Detalles Bibliográficos
Autores principales: Mobini, Moein, Radbakhsh, Shabnam, Kubaski, Francyne, Eshraghi, Peyman, Vakili, Saba, Vakili, Rahim, Khalili, Manijeh, Varesvazirian, Majid, Jamialahmadi, Tannaz, Alamdaran, Seyed Ali, Sayedi, Seyed Javad, Rajabi, Omid, Emami, Seyed Ahmad, Reiner, Željko, Sebkar, Amirhossein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745869/
https://www.ncbi.nlm.nih.gov/pubmed/35011993
http://dx.doi.org/10.3390/jcm11010247
_version_ 1784630451038584832
author Mobini, Moein
Radbakhsh, Shabnam
Kubaski, Francyne
Eshraghi, Peyman
Vakili, Saba
Vakili, Rahim
Khalili, Manijeh
Varesvazirian, Majid
Jamialahmadi, Tannaz
Alamdaran, Seyed Ali
Sayedi, Seyed Javad
Rajabi, Omid
Emami, Seyed Ahmad
Reiner, Željko
Sebkar, Amirhossein
author_facet Mobini, Moein
Radbakhsh, Shabnam
Kubaski, Francyne
Eshraghi, Peyman
Vakili, Saba
Vakili, Rahim
Khalili, Manijeh
Varesvazirian, Majid
Jamialahmadi, Tannaz
Alamdaran, Seyed Ali
Sayedi, Seyed Javad
Rajabi, Omid
Emami, Seyed Ahmad
Reiner, Željko
Sebkar, Amirhossein
author_sort Mobini, Moein
collection PubMed
description Background and Aims: Niemann–Pick disease (NPD) types A (NPA) and B (NPB) are caused by deficiency of the acid sphingomyelinase enzyme, which is encoded by the SMPD1 gene, resulting in progressive pathogenic accumulation of lipids in tissues. Trehalose has been suggested as an autophagy inducer with therapeutic neuroprotective effects. We performed a single-arm, open-label pilot study to assess the potential efficacy of trehalose treatment in patients with NPA and NPB patients. Methods: Five patients with NPD type A and B were enrolled in an open-label, single-arm clinical trial. Trehalose was administrated intravenously (IV) (15 g/week) for three months. The efficacy of trehalose in the management of clinical symptoms was evaluated in patients by assessing the quality of life, serum biomarkers, and high-resolution computed tomography (HRCT) of the lungs at the baseline and end of the interventional trial (day 0 and week 12). Results: The mean of TNO-AZL Preschool children Quality of Life (TAPQOL) scores increased in all patients after intervention at W12 compared to the baseline W0, although the difference was not statistically significant. The serum levels of lyso-SM-509 and lyso-SM were decreased in three and four patients out of five, respectively, compared with baseline. Elevated ALT and AST levels were decreased in all patients after 12 weeks of treatment; however, changes were not statistically significant. Pro-oxidant antioxidant balance (PAB) was also decreased and glutathione peroxidase (GPX) activity was increased in serum of patients at the end of the study. Imaging studies of spleen and lung HRCT showed improvement of symptoms in two patients. Conclusions: Positive trends in health-related quality of life (HRQoL), serum biomarkers, and organomegaly were observed after 3 months of treatment with trehalose in patients with NPA and NPB. Although not statistically significant, due to the small number of patients enrolled, these results are encouraging and should be further explored.
format Online
Article
Text
id pubmed-8745869
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87458692022-01-11 Impact of Intravenous Trehalose Administration in Patients with Niemann–Pick Disease Types A and B Mobini, Moein Radbakhsh, Shabnam Kubaski, Francyne Eshraghi, Peyman Vakili, Saba Vakili, Rahim Khalili, Manijeh Varesvazirian, Majid Jamialahmadi, Tannaz Alamdaran, Seyed Ali Sayedi, Seyed Javad Rajabi, Omid Emami, Seyed Ahmad Reiner, Željko Sebkar, Amirhossein J Clin Med Article Background and Aims: Niemann–Pick disease (NPD) types A (NPA) and B (NPB) are caused by deficiency of the acid sphingomyelinase enzyme, which is encoded by the SMPD1 gene, resulting in progressive pathogenic accumulation of lipids in tissues. Trehalose has been suggested as an autophagy inducer with therapeutic neuroprotective effects. We performed a single-arm, open-label pilot study to assess the potential efficacy of trehalose treatment in patients with NPA and NPB patients. Methods: Five patients with NPD type A and B were enrolled in an open-label, single-arm clinical trial. Trehalose was administrated intravenously (IV) (15 g/week) for three months. The efficacy of trehalose in the management of clinical symptoms was evaluated in patients by assessing the quality of life, serum biomarkers, and high-resolution computed tomography (HRCT) of the lungs at the baseline and end of the interventional trial (day 0 and week 12). Results: The mean of TNO-AZL Preschool children Quality of Life (TAPQOL) scores increased in all patients after intervention at W12 compared to the baseline W0, although the difference was not statistically significant. The serum levels of lyso-SM-509 and lyso-SM were decreased in three and four patients out of five, respectively, compared with baseline. Elevated ALT and AST levels were decreased in all patients after 12 weeks of treatment; however, changes were not statistically significant. Pro-oxidant antioxidant balance (PAB) was also decreased and glutathione peroxidase (GPX) activity was increased in serum of patients at the end of the study. Imaging studies of spleen and lung HRCT showed improvement of symptoms in two patients. Conclusions: Positive trends in health-related quality of life (HRQoL), serum biomarkers, and organomegaly were observed after 3 months of treatment with trehalose in patients with NPA and NPB. Although not statistically significant, due to the small number of patients enrolled, these results are encouraging and should be further explored. MDPI 2022-01-04 /pmc/articles/PMC8745869/ /pubmed/35011993 http://dx.doi.org/10.3390/jcm11010247 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Mobini, Moein
Radbakhsh, Shabnam
Kubaski, Francyne
Eshraghi, Peyman
Vakili, Saba
Vakili, Rahim
Khalili, Manijeh
Varesvazirian, Majid
Jamialahmadi, Tannaz
Alamdaran, Seyed Ali
Sayedi, Seyed Javad
Rajabi, Omid
Emami, Seyed Ahmad
Reiner, Željko
Sebkar, Amirhossein
Impact of Intravenous Trehalose Administration in Patients with Niemann–Pick Disease Types A and B
title Impact of Intravenous Trehalose Administration in Patients with Niemann–Pick Disease Types A and B
title_full Impact of Intravenous Trehalose Administration in Patients with Niemann–Pick Disease Types A and B
title_fullStr Impact of Intravenous Trehalose Administration in Patients with Niemann–Pick Disease Types A and B
title_full_unstemmed Impact of Intravenous Trehalose Administration in Patients with Niemann–Pick Disease Types A and B
title_short Impact of Intravenous Trehalose Administration in Patients with Niemann–Pick Disease Types A and B
title_sort impact of intravenous trehalose administration in patients with niemann–pick disease types a and b
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745869/
https://www.ncbi.nlm.nih.gov/pubmed/35011993
http://dx.doi.org/10.3390/jcm11010247
work_keys_str_mv AT mobinimoein impactofintravenoustrehaloseadministrationinpatientswithniemannpickdiseasetypesaandb
AT radbakhshshabnam impactofintravenoustrehaloseadministrationinpatientswithniemannpickdiseasetypesaandb
AT kubaskifrancyne impactofintravenoustrehaloseadministrationinpatientswithniemannpickdiseasetypesaandb
AT eshraghipeyman impactofintravenoustrehaloseadministrationinpatientswithniemannpickdiseasetypesaandb
AT vakilisaba impactofintravenoustrehaloseadministrationinpatientswithniemannpickdiseasetypesaandb
AT vakilirahim impactofintravenoustrehaloseadministrationinpatientswithniemannpickdiseasetypesaandb
AT khalilimanijeh impactofintravenoustrehaloseadministrationinpatientswithniemannpickdiseasetypesaandb
AT varesvazirianmajid impactofintravenoustrehaloseadministrationinpatientswithniemannpickdiseasetypesaandb
AT jamialahmaditannaz impactofintravenoustrehaloseadministrationinpatientswithniemannpickdiseasetypesaandb
AT alamdaranseyedali impactofintravenoustrehaloseadministrationinpatientswithniemannpickdiseasetypesaandb
AT sayediseyedjavad impactofintravenoustrehaloseadministrationinpatientswithniemannpickdiseasetypesaandb
AT rajabiomid impactofintravenoustrehaloseadministrationinpatientswithniemannpickdiseasetypesaandb
AT emamiseyedahmad impactofintravenoustrehaloseadministrationinpatientswithniemannpickdiseasetypesaandb
AT reinerzeljko impactofintravenoustrehaloseadministrationinpatientswithniemannpickdiseasetypesaandb
AT sebkaramirhossein impactofintravenoustrehaloseadministrationinpatientswithniemannpickdiseasetypesaandb